Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) FCF Margin (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed FCF Margin for 7 consecutive years, with 64.28% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 17260.0% to 64.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 247.86%, a 30014.0% increase, with the full-year FY2025 number at 247.86%, up 30014.0% from a year prior.
  • FCF Margin was 64.28% for Q4 2025 at Beam Therapeutics, up from 891.83% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 2409.68% in Q1 2022 to a low of 834266.67% in Q1 2021.
  • A 5-year average of 63446.4% and a median of 579.01% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -36051667bps in 2021, then soared 83667634bps in 2022.
  • Beam Therapeutics' FCF Margin stood at 22.59% in 2021, then tumbled by -1611bps to 386.54% in 2022, then soared by 108bps to 32.74% in 2023, then plummeted by -823bps to 236.88% in 2024, then skyrocketed by 73bps to 64.28% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's FCF Margin are 64.28% (Q4 2025), 891.83% (Q3 2025), and 940.07% (Q2 2025).